• Core One (COOL) has acquired New Path Laboratories, a developer of functional mushroom health products
  • The company issued 5.7M common shares as total consideration
  • New Path’s vertical integration and proprietary mycelium process keep its production costs low
  • Its two retail components both specialize in non-psychedelic mushroom products
  • Core One Labs is focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy
  • Core One (COOL) is unchanged trading at $0.60 per share

Core One (COOL) has acquired New Path Laboratories, a developer of functional mushroom health products.

The company issued 5.7M common shares as total consideration.

New Path is vertically integrated, which facilitates the growth, development and distribution of its natural health products and dietary supplements from spore to sale. Its proprietary mycelium process also makes it a low-cost producer in the space.

New Path’s two retail components, Nue Mindset and Forest Garden Mushrooms, both specialize in functional non-psychedelic mushroom products.

Nue Mindset produces a Lion’s Mane mushroom powder infused with Vitamin B3.

Forest Garden produces an immune-boosting capsule line made from Chaga, Cordyceps, Reishi, Maitake and Lion’s Mane mushrooms.

“This acquisition further extends the company’s presence in the functional mushrooms space,” stated Joel Shacker, Core One’s CEO, “and also will allow the company to generate sales revenue by virtue of adding retail distribution channels to its business model and reach an exponentially growing consumer base.”

Core One Labs is focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.

Core One (COOL) is unchanged trading at $0.60 per share as of 10:46 am EST.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.